Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

4SC Discovery Receives EU Grant Worth EUR 450,000

Published: Thursday, April 17, 2014
Last Updated: Thursday, April 17, 2014
Bookmark and Share
Three-year research collaboration with the Medical Clinic of the University of Munich includes a project for identification and optimization of new compounds against a novel epigenetic target molecule.

4SC AG has announced that its subsidiary 4SC Discovery GmbH will receive a EUR 450,000 grant from the EU for the research of new compounds targeting cardiovascular diseases such as stroke.

Using this grant 4SC can apply its key epigenetic expertise in drug discovery and development, which the company had so far been focusing primarily on oncology, also in the field of cardiovascular diseases.

The collaboration of 4SC Discovery, the Medical Clinic of the University of Munich and other companies and academic working groups was launched recently and is scheduled to run for about three years. The main collaboration partner of 4SC Discovery is Prof. Dr. med. Martin Dichgans, Director of the Institute for Stroke and Dementia Research (ISD) of the Medical Clinic of the University of Munich.

The grant is part of the EU consortium 'CVgenes-at-target' (Grant Agreement Number: 601456) for the purpose of researching new therapeutic target structures for the treatment of cardiovascular diseases caused by an inflammatory reaction of the blood vessels. This project, which involves twelve partners in Europe, will be coordinated by Prof. Dr. Heribert Schunkert from the German Heart Centre in Munich.

4SC Discovery has already started its work of identifying and optimizing highly potent, selective compounds against a new epigenetic target molecule. The company will perform part of the compound screening, medicinal chemistry and the optimization of the compounds' pharmacokinetics and solubility. Preclinical trials with the compounds will be conducted at the Medical Clinic of the University of Munich to deliver the first proofs-of-concept. 4SC Discovery will retain the rights to the identified substances.

During the first part of the collaboration, the focus will be on researching the investigated epigenetic molecule as a possible therapeutic target structure for stroke. Epigenetic target structures such as histone deacetylases (HDACs) coordinate gene transcription and therefore play an important role in the development of cancer and neurological diseases. It will now be researched what role epigenetic modifications play in cardiovascular diseases. During the second part of the collaboration, additional target structures that potentially play a role in stroke development will be subjected to a compound screening and potential inhibitors will be identified and optimized.

Stroke is a consequence of cardiovascular diseases and the third most frequent cause of death in Germany. A recently conducted analysis of the global study entitled 'Global Burden of Disease' published in the renowned medical journal Lancet in January of 2014 showed that the number of younger people suffering from stroke is increasing. This is caused by risk factors such as high blood pressure, smoking, high blood sugar, lack of exercise and an unbalanced diet. In 2010, about 16.9 million people worldwide suffered a stroke and 5.9 million of them died as a result.

Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief Scientific Officer at 4SC AG, commented: 'While cardiovascular diseases were not a focus for 4SC in the past, we have built a comprehensive knowledge base regarding the effective inhibition of HDAC molecules based on our epigenetic research especially in the field of cancer. As a result, we are now also viewed as a competent partner in other therapeutic areas in which epigenetic molecules play an important role. We are pleased to start another collaboration with renowned partners such as the Medical Clinic of the University of Munich and to be able to make a contribution in the discovery of new compounds. Apart from the scientific aspect, EU funding for our activities also represents an attractive economic incentive.'

Prof. Dr. med. Martin Dichgans, Director of the Institute for Stroke and Dementia Research (ISD) at the Medical Clinic of the University of Munich, added: 'It is our objective to advance research in the field of stroke and dementia and to make a contribution to the development of entirely new treatment options. 4SC Discovery is the ideal partner for us in terms of epigenetic issues and the practical implementation of early-stage research.'

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Strengthens Patent Protection for Lead Cancer Compound Resminostat
US patent for medical use in cancer and Canadian composition of matter patent granted.
Wednesday, July 01, 2015
BEYOND RESEARCH Initiative of 4SC Discovery and CRELUX Reaches First Milestone
Compounds for inhibiting oxygen radicals and associated signalling pathways optimized for developing innovative therapies for degenerative diseases.
Tuesday, January 13, 2015
4SC Announces Financial Results for a Successful Year 2012
Consolidated results considerably improved due to rising revenue and reduced costs.
Tuesday, March 26, 2013
4SC AG Further Strengthens Supervisory Board
Appointment of Dr Irina Antonijevic and Mr Klaus Kühn.
Monday, December 31, 2012
4SC's Successful Development Continues in Third Quarter of 2012
Consolidated financial results improved in third quarter and first nine months.
Friday, November 09, 2012
4SC Announces Financial Results for the First Quarter of 2012
Company has made a successful start to 2012.
Monday, October 22, 2012
4SC Receives Milestone Payment from Research Collaboration with SKK
4SC had contributed its know-how in the field of medicinal chemistry to investigate new classes of substances for the potential therapy of metabolic diseases.
Monday, October 15, 2012
4SC Discovery, Crelux and Ribological Launch Collaboration
Collaboration for the discovery and optimization of new anti-cancer drugs.
Tuesday, July 17, 2012
4SC's Vidofludimus Shows Preclinical Evidence in a Kidney Transplantation Model
New preclinical data published in peer-reviewed article in Transplantation.
Tuesday, June 19, 2012
4SC AG Announces Election of Dr Thomas Werner to Chairman of the Supervisory Board
Company also elected Dr Manfred Rüdiger as its new deputy chairman.
Thursday, June 14, 2012
4SC's Partner Yakult Honsha Starts Clinical Development with Cancer Compound Resminostat in Japan
The Phase I study will assess safety of resminostat in Japanese patients, which is a prerequisite of the drug's further late-stage clinical development in Japan.
Monday, May 21, 2012
4SC Discovery and CRELUX Enter into a Strategic Alliance
Strategic partnership for integrated drug discovery services.
Monday, April 23, 2012
4SC to Present at Two Upcoming Investor Conferences
Future leaders in the Biotech Industry conference, 20 April 2012 in New York.
Tuesday, April 17, 2012
Henkel and 4SC Discovery Start Research Collaboration in Compound Screening
Aim is to identify new and more effective laundry detergent ingredients.
Monday, April 09, 2012
4SC’s Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation
European Medicines Agency recommend resminostat as orphan medicinal product for the treatment of Hodgkin’s Lymphoma.
Friday, October 14, 2011
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos